A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

• Published in: Leukemia Vol. 31; no. 4; pp. 896 - 902
• Main Authors: Tefferi, A, Al-Ali, H K, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J-J, Mesa, R, Passamonti, F, Ribrag, V, Schiller, G, Vannucchi, A M, Zhou, D, Reiser, D, Zhong, J, Gale, R P
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.04.2017; Nature Publishing Group
• Subjects: 631/92/436/108; 692/308/2779/777; 692/699/1541/13; 692/699/1541/1990/2331; 692/700/565; Adult; Aged; Aged, 80 and over; Anemia; Biomarkers; Bone marrow; Cancer Research; Comparative analysis; Complications and side effects; Critical Care Medicine; Dosage and administration; Drug dosages; Erythrocyte Transfusion - methods; FDA approval; Female; Hematology; Humans; Immunologic Factors - administration & dosage; Immunologic Factors - adverse effects; Immunologic Factors - therapeutic use; Intensive; Internal Medicine; Leukemia; Male; Medicine; Medicine & Public Health; Middle Aged; Myelofibrosis; Myeloproliferative disorders; Myeloproliferative Disorders - complications; Myeloproliferative Disorders - diagnosis; Oncology; Original; original-article; Phenotype; Placebos; Pomalidomide; Primary Myelofibrosis - diagnosis; Primary Myelofibrosis - etiology; Primary Myelofibrosis - therapy; Response rates; Risk factors; Thalidomide - administration & dosage; Thalidomide - adverse effects; Thalidomide - analogs & derivatives; Thalidomide - therapeutic use; Treatment Outcome; Tumors; Workflow; Beijing China; Italy; United States > US; China

RBC-transfusion dependence is common in persons with myeloproliferative neoplasm (MPN)-associated myelofibrosis. The objective of this study was to determine the rates of RBC-transfusion independence after therapy with pomalidomide vs placebo in persons with MPN-associated myelofibrosis and RBC-tran...